Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

The LBI-HTA in Austria published 7 HTA reports relevant for medical devices in 2017; none of the technologies was recommended for inclusion without limitations

The Ludwig Boltzmann Institute– Health Technology Assessment (LBI-HTA) is the main health technology appraisal body in Austria. It is an independent organization that on request provides scientific support for decision-making regarding the inclusion of health technologies (medical devices and in-vitro diagnostics) into the national benefit catalogue by the Ministry of Health. LBI-HTA produces different types of reports. The most relevant reports regarding market access of medical devices are so-called decision support documents (DSD) which are systematic, scientific review papers with a focus on efficacy and safety of technology (HTA reports).

In decision support documents, the LBI-HTA gives its evidence-based recommendation in the form of four categories:

  1. Recommendation for inclusion
  2. Limmited recommendation for inclusion
  3. Preliminary no recommendation for inclusion
  4. No recommendation for inclusion

Recommendations by the LBI-HTA are not binding, yet, they are in 90 % of cases followed by the decision maker, the Federal Health Commission (BGK).

During the year 2017, the LBI-HTA produced seven decision support documents with relevance for medical devices of which 2 were updates of previous reports. Following were the report titles and LBI-HTA’s recommendation expressed in category numbers described above:

  • Extracorporeal cytokine haemadsorption therapy in patients with sepsis or SIRS; 3
  • Prostate artery embolisation for benign prostatic hyperplasia; 3
  • Radiofrequency ablation for metastatic spinal lesions; 2
  • Electric stimulation therapy (EST) in patients with gastroesophageal reflux disease (GERD); 3
  • Leadless pacemakers for right ventricle pacing, update; 3
  • Repetitive transcranial magnetic stimulation for treatment-resistant major depression; 2
  • Percutaneous volume reduction of the disc with focus on chemonucleolysis, update
    • Recommendation for chemonucleolysis: 2
    • Recommendation for further percutaneous intervertebral disk volume reduction (percutaneous nucleotomy, percutaneous laser disc decompression or IDET): 3

All reports published in 2017 are available in the LBI-HTA repository.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.